![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Doravirine 100 mg QD vs Efavirenz +TDF/FTC in ART-Naïve HIV+ Patients: Week 48 Results
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Jose M. Gatell1; Francois Raffi2; Andreas Plettenberg3; Don Smith4; Joaquin Portilla5; Christian Hoffmann6; Keikawus Arasteh7; Melanie Thompson8; Xia Xu9; Hedy Teppler9 for the 1439-007 Study Team
1Hospital Clinic/IDIBAPS, University of Barcelona, Barcelona, Spain; 2COREVIH Pays de Loire, France; 3ifi-Institute for Infections, Hamburg, Germany; 4Albion Centre, Sydney, Australia; 5University Miguel Hernandez, Alicante, Spain; 6ICH Study Center, Hamburg, Germany; 7EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 8AIDS Research Consortium of Atlanta, Atlanta, GA, USA; 9Merck & Co., Inc., Kenilworth, NJ, USA
![CROI1](../images/022616/022616-7/CROI1.gif)
![CROI2](../images/022616/022616-7/CROI2.gif)
![CROI3](../images/022616/022616-7/CROI3.gif)
![CROI4](../images/022616/022616-7/CROI4.gif)
![CROI5](../images/022616/022616-7/CROI5.gif)
![CROI6](../images/022616/022616-7/CROI6.gif)
![CROI7](../images/022616/022616-7/CROI7.gif)
![CROI8](../images/022616/022616-7/CROI8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|